Review





Similar Products

cat 233 fb cf ndiff  (TaKaRa)
96
TaKaRa cat 233 fb cf ndiff
Cat 233 Fb Cf Ndiff, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/pm40132585-652-101-107?v=TaKaRa
Average 96 stars, based on 1 article reviews
cat 233 fb cf ndiff - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
fgf2  (R&D Systems)
95
R&D Systems fgf2
Fgf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/10__3390_slash_mi17020199-62-40-43?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
fgf2 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
233 fb  (R&D Systems)
96
R&D Systems 233 fb
233 Fb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/pm41145913-284-57-54?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
233 fb - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
bfgf  (R&D Systems)
95
R&D Systems bfgf
a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium <t>containing</t> <t>BMP4</t> and <t>bFGF</t> for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.
Bfgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/pmc12540785-396-24-27?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
bfgf - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
human basic fibroblast growth factor  (R&D Systems)
95
R&D Systems human basic fibroblast growth factor
a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium <t>containing</t> <t>BMP4</t> and <t>bFGF</t> for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.
Human Basic Fibroblast Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/pmc12482506-62-22-28?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
human basic fibroblast growth factor - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
fibroblast growth factor fgf  (R&D Systems)
95
R&D Systems fibroblast growth factor fgf
a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium <t>containing</t> <t>BMP4</t> and <t>bFGF</t> for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.
Fibroblast Growth Factor Fgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/bio_rxiv__2025__07__28__667194-47-12-16?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
fibroblast growth factor fgf - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
recombinant human fgf2  (R&D Systems)
95
R&D Systems recombinant human fgf2
a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium <t>containing</t> <t>BMP4</t> and <t>bFGF</t> for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.
Recombinant Human Fgf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/pm40628749-508-29-32?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
recombinant human fgf2 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
fibroblast growth factor  (R&D Systems)
95
R&D Systems fibroblast growth factor
a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium <t>containing</t> <t>BMP4</t> and <t>bFGF</t> for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.
Fibroblast Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/233-fb-cf/bio_rxiv__2025__04__01__646442-191-114-118?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
fibroblast growth factor - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

Image Search Results


a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium containing BMP4 and bFGF for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: APOA1 binding protein promotes lymphatic cell fate and lymphangiogenesis by relieving caveolae-mediated inhibition of VEGFR3 signaling

doi: 10.1038/s41467-025-60611-w

Figure Lengend Snippet: a Representative confocal images of Prox1 + cells in the fli1a:egfp and apoa1bp2 −/− ; fli1a:egfp at 4 dpf following immunostaining using GFP and Prox1 antibodies. Arrows show the Prox1 + LECs in TD. Blood vessels are labeled in green, and Prox1 staining is shown in red. Data are pooled from 3 independent experiments. b Quantitative data of Prox1 + LEC in TD of 7 somites. Mean ± SE, n = 23 ( fli1a:egfp ) and n = 28 ( apoa1bp2 −/− ; fli1a:egfp) embryos; unpaired two-sided t -test with Welch’s correction. c Scheme illustration of mESC to LEC differentiation. The embryoid bodies (EBs) of mESCs were prepared and cultured in the EC differentiation medium containing BMP4 and bFGF for 3 days. Recombinant VEGFA and VEGFC in combination or AIBP were supplemented at day 3 and remained in culture for additional 4 days. d qPCR analysis of the expression of LEC-associated Lyve1 and Prox1 and endothelial cell marker Pecam1 at the indicated time points of mESC to LEC differentiation. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. The P-values comparing control and AIBP-treated samples are shown. e qPCR analysis of the expression of Vegfc and Adamts3 . Mean ± SD, n = 3-4; two-way ANOVA with Tukey’s post-hoc test. f Effect of VEGFR3 and NOTCH inhibition on mESC to LEC differentiation. The murine ESCs were subjected to LEC differentiation as described in panel c in the presence or absence VEGFR3 inhibitor SAR ( SAR13165 ) or NOTCH inhibitor DAPT from day 3 to day 7. qPCR analysis of Prox1 , Lyve1 , and Pecam1 expression was performed. Mean ± SD, n = 3 independent repeats; two-way ANOVA with Tukey’s post-hoc test. ****p < 0.0001. Scale: 50 µm. Source data are provided as a Source Data file.

Article Snippet: Briefly, mESCs were seeded onto collagen IV-coated plates and maintained in LEC differentiation medium supplemented with 2 ng/ml BMP4 (Cat #PHC9534, Gibco), 10 ng/ml bFGF (Cat #233-FB/CF, R&D systems), 50 ng/ml VEGFA (Cat #293, R&D systems), and 50 ng/ml VEGFC (Cat #2179-VC, R&D systems) for 7 days.

Techniques: Immunostaining, Labeling, Staining, Cell Culture, Recombinant, Expressing, Marker, Control, Inhibition